Editorial: Fighting against coronary and peripheral calcification during percutaneous interventions
Frontiers in Cardiovascular Medicine · 20.11.2026 · 13
DOI: 10.3389/fcvm.2026.2002420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cardiovascular Medicine, online erschienen am 20.11.2026. Verfasst von Zoltán Ruzsa und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Calcified vascular disease is now one of the defining challenges of contemporary percutaneous intervention. The central question is no longer only whether a lesion can be crossed or whether a stent can be delivered. Operators must decide how calcium should be modified, how much lesion preparation is enough, which imaging findings justify escalation, and whether the chosen device strategy improves outcomes at a cost that is defensible for patients and health systems. 20 The manuscripts considered in this editorial approach these questions from complementary directions: calcium-modifying balloons, rotational atherectomy in chronic total occlusion, ex vivo diode-laser plaque modification, the triglyceride-glucose index and coronary in-stent restenosis, and a cost comparison of atherectomy plus balloon angioplasty versus stenting in lower-limb peripheral artery disease [1][2][3][4][5]. Together, they support a morphology-tailored, imaging-guided, outcomeconscious approach rather than a device-first strategy. A useful editorial theme is restraint: calcium therapy should escalate when morphology and mechanics require it, and de-escalate when a simpler preparation achieves the same procedural endpoint.Coronary calcification is a mechanical disease as much as an anatomic one. Angiography may suggest calcium, but it cannot reliably define calcium arc, thickness, depth, nodularity, or the risk of stent underexpansion. Intravascular imaging therefore has moved from an adjunctive technique to a central decision tool in complex calcified PCI. When the lesion is clinically important or technically demanding, imaging should define the problem before the operator commits to a plaque-modification strategy. The procedural endpoint should be adequate lesion compliance and expansion, not maximal device use.Intravascular palpation is the practical counterpart of intravascular imaging. The persistence of a balloon waist, the pressure required to obtain expansion, elastic recoil after deflation, and the ease or resistance with which a specialty balloon, lithotripsy balloon, or atherectomy device crosses the lesion all provide mechanical feedback from the plaque. This information is subjective and should 40 not replace IVUS or OCT, but it helps the operator judge whether calcium modification has changed lesion compliance enough for safe drug delivery or stent expansion. A useful future endpoint for plaque-preparation devices may be the conversion of this operator-level tactile information into reproducible measures of lesion compliance and residual recoil.The review by Colletti and colleagues places scoring balloons, cutting balloons, and ultra-highpressure non-compliant balloons in a practical framework for balloon-crossable calcified lesions [4]. Scoring and cutting balloons offer controlled focal stress and plaque incision, whereas ultra-highpressure balloons may help in resistant or undilatable segments. The main message is that lesion morphology should determine escalation. Deep calcium, nodular calcium, poor compliance, and device uncrossability may still require intravascular lithotripsy or atherectomy. 50 Rotational atherectomy remains important when severe coronary calcification prevents adequate balloon preparation. In 119 patients undergoing RA-assisted PCI for single-vessel CTO, procedural success was high, and six-month MACCE rates were numerically lower in right coronary artery CTO than in left coronary CTO, with the RCA versus non-RCA comparison reaching significance in post hoc analysis [3]. Because event numbers were small and the comparison was exploratory, vesseldisease. Plaque preparation in peripheral artery disease should therefore not be extrapolated directly from coronary PCI. The goals may include luminal gain, recoil reduction, avoidance of a permanent implant, wound healing, walking capacity, and prevention of repeat revascularization.The peripheral cost-effectiveness manuscript is especially relevant. In a 1:1 propensity-matched cohort of 160 patients per group, atherectomy plus balloon angioplasty and balloon angioplasty plus paclitaxel-eluting nitinol stenting showed similar 12-month patency, ankle-brachial index, walking distance, Rutherford class, Peripheral Artery Questionnaire score, and safety outcomes [5]. The atherectomy strategy was associated with substantially lower one-year total cost, driven mainly by device and implant costs. Because the study was powered for superiority rather than non-inferiority, the result should be framed as no detected difference in outcomes with lower observed cost, not 80 definitive therapeutic equivalence. This finding should sharpen decision-making. In peripheral calcified disease, atherectomy, specialty balloons, drug-coated balloons, drug-eluting stents, covered stents, and plain balloon angioplasty all have plausible roles. Each device also adds cost, procedural time, deliverability constraints, and potential complications. A value-based peripheral calcium strategy should state the reason for each step: lesion crossing, debulking, compliance change, preparation before drug delivery, bailout after dissection, avoidance of a permanent implant, or protection from recoil.A practical peripheral algorithm should separate plaque preparation from definitive therapy. Preparation should be judged by whether it changes lesion mechanics enough to allow durable treatment with the least necessary implant burden. Definitive therapy should then be selected 90 according to vessel segment, lesion length, residual stenosis, flow-limiting dissection, expected durability, bleeding risk, patient mobility, wound status, and local device economics.Across coronary and peripheral intervention, calcified plaque preparation should be purposeful, measured, and patient-specific. Imaging should define morphology; the device should solve a clearly 95 stated mechanical problem; the clinical strategy should incorporate patient biology; and value should be treated as part of clinical judgment. Future studies should standardize definitions of calcium modification, procedural success, expansion, complications, and follow-up. Small series remain useful for describing technique, but they should avoid causal language. Comparative observational studies should prespecify superiority or non-inferiority logic, and biomarker studies should move 100 beyond association toward incremental prediction and intervention-linked clinical pathways. The field is no longer defined simply by whether calcium can be crossed, cracked, ablated, compressed, or debulked. It is defined by whether mechanical modification is matched to morphology and justified by durable clinical and economic benefit.
Zitieren
APA
Ruzsa, Z., Tóth, G. G., & Gil, R. (2026). Editorial: Fighting against coronary and peripheral calcification during percutaneous interventions. Frontiers in Cardiovascular Medicine, 13. https://doi.org/10.3389/fcvm.2026.2002420
Vancouver
Ruzsa Z, Tóth GG, Gil R. Editorial: Fighting against coronary and peripheral calcification during percutaneous interventions. Frontiers in Cardiovascular Medicine. 2026;13. doi:10.3389/fcvm.2026.2002420
BibTeX
@article{Ruzsa2026,
author = {Ruzsa, Zoltán and Tóth, Gábor G. and Gil, Robert},
title = {Editorial: Fighting against coronary and peripheral calcification during percutaneous interventions},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fcvm.2026.2002420}
}
EUVIMED